Copyright
©The Author(s) 2017.
World J Gastroenterol. Jun 28, 2017; 23(24): 4399-4406
Published online Jun 28, 2017. doi: 10.3748/wjg.v23.i24.4399
Published online Jun 28, 2017. doi: 10.3748/wjg.v23.i24.4399
Table 1 Comparison of clinicopathological characteristics of patients with or without para-aortic nodesinvolvement
Total(n = 151) | PALNs-(n = 126) | PALNs+(n = 25) | P value | |
Mean/median age | 65/67 | 65/66 | 65/68 | |
Sex | ||||
F | 75 | 59 | 16 | 0.13 |
M | 76 | 67 | 9 | |
Type of surgery | ||||
PD | 146 | 122 | 24 | 1.00 |
TP | 5 | 4 | 1 | |
Vascular resection | 29 | 21 | 8 | 0.09 |
Tumor (T) | ||||
1 | 6 | 6 | 0 | 0.50 |
2 | 17 | 14 | 3 | 1.00 |
3 | 107 | 90 | 17 | 0.80 |
4 | 21 | 16 | 5 | 0.50 |
Nodes status (N) | ||||
Neg | 39 | 39 | 0 | 0.003 |
Pos | 112 | 87 | 25 | |
Grading (G) | ||||
1 | 15 | 11 | 4 | 0.20 |
2 | 89 | 77 | 12 | 0.20 |
3 | 47 | 38 | 9 | 0.60 |
Radicality | ||||
Yes | 113 | 100 | 13 | 0.009 |
No | 38 | 26 | 12 | |
Adjuvant therapy | ||||
Yes | 143 | 120 | 23 | 0.74 |
No | 8 | 6 | 0 |
Table 2 Univariate overall survival analysis of prognostic factors for patients with pancreatic cancer
Mean survival time (mo) (95%CI) | Median survival time (mo) (95%CI) | P value | |
Grading (G) | |||
1-2 | 39.55 (32.36-46.74) | 24.00 (19.87-28.13) | < 0.001 |
3 | 16.42 (12.86-19.98) | 14.00 (12.57-15.43) | |
Radicality | |||
R0 | 35.88 (29.46-42.31) | 22.00 (18.36-25.64) | 0.004 |
R1 | 19.99 (12.62-27.38) | 13.00 (11.45-14.55) | |
Stage | |||
I-II | 34.82 (28.47-41.18) | 21.00 (17.79-24.21) | 0.03 |
III-IV | 23.29 (14.70-31.87) | 14.00 (11.40-16.59) | |
Lymph nodes status | |||
Neg | 43.29 (30.37-56.21) | 25.00 (17.055-32.95) | 0.04 |
Pos | 27.27 (22.52-32.02) | 18.00 (14.65-21.35) | |
Number of positive lymph nodes | |||
< 3 | 26.62 (20.87-32.35) | 19.00 (13.09-24.90) | 0.74 |
> 3 | 28.39 (20.04-36.74) | 17.00 (12.93-21.07) | |
Lymph node ratio | |||
≤ 0.13 | 31.31 (23.69-38.93) | 20.00 (15.57-24.43) | 0.28 |
0.13-0.2 | 25.11 (13.23-36.99) | 14.00 (9.87-18.13) | |
> 0.2 | 23.29 (16.98-29.61) | 18.00 (14.57-21.43) | |
Para-aortic lymph nodes status | |||
Neg | 42.06 (29.22-54.89) | 25.00 (17.17-32.83) | 0.02 |
Pos | 27.27 (22.54-32.02) | 18.00 (14.64-21.35) |
Table 3 Univariate disease-free survival analysis of prognostic factors for patients with pancreatic cancer
Mean DFI time (mo) (95%CI) | Median DFI time (mo) (95%CI) | P value | |
Grading (G) | |||
1-2 | 32.438 (24.808-40.068) | 13.000 (8.597-17.403) | < 0.01 |
3 | 10.438 (8.011-12.865) | 8.000 (7.183-8.817) | |
Radicality | |||
R0 | 29.886 (22.892-36.880) | 12.000 (9.280-14.720) | 0.001 |
R1 | 12.708 (6.744-18.671) | 8.000 (6.256-9.744) | |
Staging | |||
I-II | 27.222 (20.732-33.711) | 12.000 (9.814-14.186) | 0.126 |
III-IV | 19.772 (9.939-29.604) | 8.000 (6.976-9.0224) | |
Lymph nodes status | |||
Neg | 34.386 (20.868-47.904) | 13.000 (9.523-16.477) | 0.106 |
Pos | 21.468 (16.504-26.432) | 10.000 (7.686-12.314) | |
Number of positive lymph nodes | |||
< 3 | 30.817 (21.628-40.006) | 10.000 (6.746-13.254) | 0.150 |
> 3 | 20.326 (14.615-26.036) | 11.000 (8.082-13.918) | |
lymph node ratio | |||
≤ 0.13 | 30.576 (22.593-38.560) | 12.000 (9.211-14.789) | 0.155 |
0.13-0.2 | 17.500 (5.595-29.405) | 8.000 (6.614-9.366) | |
> 0.2 | 17.397 (11.191-23.603) | 13.000 (8.840-17.160) | |
Para-aortic lymph nodes status | |||
Neg | 28.206 (21.656-34.756) | 12.000 (9.808-14.192) | 0.005 |
Pos | 11.957 (6.132-17.781) | 8.000 (6.853-9.147) |
Table 4 Multivariate analysis for overall survival and disease-free survival in 151 patients resected for pancreatic adenocarcinoma
Overall survival | Disease-free survival | |||
HR (95%CI) | P value | HR (95%CI) | P value | |
Grading | 2.518 (1.677-3.780) | 0.000 | 2.266 (1.498-3.428) | 0.000 |
Stage | 1.137 (0.676-1.915) | 0.628 | 0.960 (0.570-1.615) | 0.877 |
PALNs status | 1.376 (0.776-2.441) | 0.275 | 1.519 (0.869-2.656) | 0.143 |
- Citation: Sperti C, Gruppo M, Blandamura S, Valmasoni M, Pozza G, Passuello N, Beltrame V, Moletta L. Para-aortic node involvement is not an independent predictor of survival after resection for pancreatic cancer. World J Gastroenterol 2017; 23(24): 4399-4406
- URL: https://www.wjgnet.com/1007-9327/full/v23/i24/4399.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i24.4399